All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
– Data readouts expected before year end
– Previously reported preliminary efficacy data on its Phase 1B/2 clinical trial with Annamycin in monotherapy treatment of STS lung mets with >60% of the subjects exhibiting stable disease after two cycles of treatment
Read more at prnewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| MBRX | 1.1600 | -0.1000 | -7.94% |
| Moleculin Biotech CS | |||
/A%20Palantir%20office%20building%20in%20Tokyo_%20Image%20by%20Hiroshi-Mori-Stock%20via%20Shutterstock_.jpg)
/Super%20Micro%20Computer%20Inc%20logo%20on%20phone%20and%20stock%20data-by%20Poetra_RH%20via%20Shutterstock.jpg)
/Palantir%20by%20rblfmr%20via%20Shutterstock.jpg)